BMS Reverse Cholesterol Transport (RCT) Study

University of Pennsylvania

Status

Completed

Conditions

Healthy

Treatments

Other: 3H-Cholesterol

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01031862

810035

CV 197-003

Details and patient eligibility

About

The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma, lipoproteins and feces.

Full description

The study will use 3H-cholesterol bound to albumin (particulate cholesterol) to assess the ability of HDL to transport cholesterol to the liver to be eliminated. This process is called Reverse Cholesterol transport and is one of the main mechanisms by which HDL protect against atherosclerotic cardiovascular disease. The availability of a method to assess RCT is important for the development of new drugs which affect RCT and may result in useful treatments for atherosclerosis.

This study will evaluate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma and lipoproteins. The study population is healthy volunteers.

Enrollment

12 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men and women between the ages of 18 and 70
Female subjects must be of non-childbearing potential. They must have been surgically sterilized at least 6 months prior to screening or be postmenopausal. Postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion. .
Subjects must be in good overall health
Subjects must be able to comprehend and willing to provide a signed IRB approved Informed Consent Form.
Subjects must be willing to comply with all study-related procedures.

Exclusion criteria

Known cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease
History of diabetes mellitus or fasting glucose > 126 mg/dL at the screening visit
History of any other endocrine disease
History of a non-skin malignancy within the previous 5 years
Anemia; Hemoglobin less than 10 g/dL
Renal insufficiency as defined by creatinine ³ 1.3 mg/dl
Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition
History of hypertension
Use of warfarin, or any known coagulopathy and /or elevated PT/PTT >1.5 x ULN
Self-reported history of HIV positive
Previous organ transplantation
Clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests such as ALT or AST > 1x ULN, or self-reported history of positive Hepatitis B or Hepatitis C test result
Any major surgical procedure that occurred within the previous 3 months of the screening visit
Use of tobacco products currently or during the previous 30 days
History of drug abuse (< 3 years)
Regular use of alcoholic beverages (> 2 drinks/day)
Body mass index (BMI) > 30 kg/m2 or < 18.5 kg/m2
Participation in an investigational drug study within 6 weeks prior to the screening visit
Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study will be excluded.
Use of lipid lowering drugs within the 6 weeks prior to dosing or during the study
Use of other prescription or non-prescription drugs (including vitamins and herbal supplements, but excluding replacement hormone therapy) within 2 weeks prior to dosing or during the study, however, acetaminophen up to 2g/day is acceptable.
Male subjects who plan to conceive a child within 3 months of the conclusion of the study.